Pricing Log in Create free account

Cellectis S.A. (CLLS) vs OnKure Therapeutics, Inc. (OKUR)

Cellectis S.A. and OnKure Therapeutics, Inc. are both Biotechnology companies. Cellectis S.A. and OnKure Therapeutics, Inc. are of similar size ($93.2M and $90.4M). OnKure Therapeutics, Inc. has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, OnKure Therapeutics, Inc. leads on 9 and Cellectis S.A. on 4.

Valuation

Metric CLLS OKUR Biotechnology median
P/E n/m n/m 8.68
P/S 1.99 n/m 10.29
P/B 3.09 0.70 2.40
Price to free cash flow n/m n/m 20.52
EV/EBITDA n/m 0.92 0.68
EV/Sales 0.53 n/m 10.15
Earnings yield (51.91%) (145.23%) (28.86%)
Free cash flow yield (36.43%) (39.83%) (22.44%)

Profitability

Metric CLLS OKUR Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (90.88%) 0.00% 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) (46.91%) (56.66%)
Return on assets (21.02%) (44.24%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS OKUR Biotechnology median
Revenue growth (TTM) 0.61% — 5.64%
EPS growth (last fiscal year) (63.41%) 71.20% 30.08%
Revenue growth, 5-year CAGR (0.70%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS OKUR Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 26.75 4.72
Net debt to EBITDA 9.54 0.95 0.96

Dividend

Metric CLLS OKUR Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CLLS OKUR Biotechnology median
Market cap 90.41m 93.15m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack